Research Focus Areas:
The overall goal of my laboratory is to understand signaling mechanisms involved in regulating the pulmonary vasculature at the level of the endothelium. Work in the laboratory has identified several signaling molecules, including protein kinase Cδ, SHP2, and PTP1B, and endosomal regulating proteins, p18, Rab4 and Rab9 GTPase, that actively regulate the lung endothelial barrier in settings of injury and at baseline. Our models incorporate both in vitro and in vivo approaches. Additional research interests include understanding the heterogeneity of the endothelium in different vascular beds and organ subcompartments. Also, work is ongoing investigating the mechanism by with the atrial natriuretic peptide (ANP) attenuates edemagenic responses of the lung endothelium.
Current Funding:
|
Funding Agency: NIH NHLBI T32HL134625 (Harrington, Bennett, Levy, & Rounds)
Role: Principal Investigator
Title: Brown Respiratory Research Training Program
Funding period: 04/01/17-08/31/21
Direct Costs: $498,064
|
|
|
Funding Agency: NIH NIGMS P20GM103652 (Rounds)
Role: Deputy Director; Core Director
Title: Endothelial Injury And Repair: Cardiopulmonary Vascular Biology COBRE
Funding Period: 9/20/2013-5/31/2018
Direct Costs: $1,978,405 (Harrington: $289,679)
|
|
|
Funding Agency: NIH NHLBI R01HL123965 (Klinger)
Role: co-Principal Investigator
Title: The Role of NPR-C in Modulation of Acute Lung Injury
Funding Period: 7/1/2015-3/31/2019
Direct Costs: $266,309 |
|
|
Funding Agency: NIH NHLBI R25HL088992
Role: Principal Investigator
Title: Short-Term Training Program to Increase Diversity in Health-Related Research
Funding Period: 7/1/2012-6/30/2022
Direct Costs: $93,575 |
|
|
Funding Agency: NIH NIGMS R25GM083270 (Campbell)
Role: co-Principal Investigator
Title: Initiative to Maximize Student Development
Funding Period: 3/1/2011-3/31/2022
Direct Costs: $718,847 |
|
|
Funding Agency: NIH NHLBI T35HL094308
Role: Principal Investigator
Title: Alpert Medical Student Summer Research Program
Funding Period: 12/1/2014-8/31/2019
Direct Costs: $44,673 |
Recent Publications:
-
Aldosari S, Awad M, Harrington EO Subcellular Reactive Oxygen Species (ROS) in Cardiovascular Pathophysiology. Antioxidants (Basel). 2018 Jan 16;7(1). pii: E14.
-
Harrington EO, Vang A, Braza J, Shil A, Chichger H. Activation of the sweet taste receptor, T1R3, by the artificial sweetener sucralose regulates the pulmonary endothelium. Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L165-L176.
-
Shafique E, Torina A, Reichert K, Colantuono B, Nur N, Zeeshan K, Ravichandran V, Liu Y, Feng J, Zeeshan K, Benjamin LE, Irani K, Harrington EO, Sellke FW, Abid MR. Mitochondrial redox plays a critical role in the paradoxical effects of NAPDH oxidase-derived ROS on coronary endothelium. Cardiovasc Res. 2017 Feb;113(2):234-246.
-
Chichger H, Braza J, Duong H, Boni G, Harrington EO. Select Rab GTPases Regulate the Pulmonary Endothelium via Endosomal Trafficking of Vascular Endothelial-Cadherin. Am J Respir Cell Mol Biol. 2016 Jun;54(6):769-81.
-
Chichger H, Braza J, Duong H, Stark M, Harrington EO. Neovascularization in the pulmonary endothelium is regulated by the endosome: Rab4-mediated trafficking and p18-dependent signaling. Am J Physiol Lung Cell Mol Physiol. 2015 Oct 1;309(7):L700-9.
-
Chichger H, Vang A, O'Connell KA, Zhang P, Mende U, Harrington EO, Choudhary G. PKC δ and βII regulate angiotensin II-mediated fibrosis through p38: a mechanism of RV fibrosis in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2015 Apr 15;308(8):L827-36.
-
Chichger H, Duong H, Braza J, Harrington EO. p18, a novel adaptor protein, regulates pulmonary endothelial barrier function via enhanced endocytic recycling of VE-cadherin. FASEB J. 2015 Mar;29(3):868-81.
-
Chichger H, Braza J, Duong H, Harrington EO. SH2 domain-containing protein tyrosine phosphatase 2 and focal adhesion kinase protein interactions regulate pulmonary endothelium barrier function. Am J Respir Cell Mol Biol. 2015 Jun;52(6):695-707.
-
Klinger JR, Tsai SW, Green S, Grinnell KL, Machan JT, Harrington EO. Atrial natriuretic peptide attenuates agonist-induced pulmonary edema in mice with targeted disruption of the gene for natriuretic peptide receptor-A. J Appl Physiol (1985). 2013 Feb;114(3):307-15.